The article reports on the U.S. Food & Drug Administration accelerated approval granted to bevacizumab in combination with paclitaxel for the treatment of metastatic breast cancer. The approval of the drug was based on findings from the E2100, an international, multi-center, randomized, controlled study.

ACCESSION #

31672177

Related Articles

The article reports on the recommendation of the Oncologic Drugs Advisory Committee of the U.S. Food and Drugs Administration (FDA) to remove the indication for breast cancer treatment for bevacizumab, brand name Avastin.

The article reports on the recommendation by the Oncologic Drugs Advisory committee of the U.S. Food and Drug Administration (FDA) for the removal of the indication for breast cancer treatment for bevacizumab (Avastin) as it provided no survival benefit in combination with docetaxel and...

In this article the author reflects upon the supplemental Biologics License Applications (sBLAs) submitted by Genentech Inc. to the U.S. Food and Drug Administration (FDA), for Avastin drug in breast cancer treatment. The author talks about the likelihood of company getting the approval on the...

The article reports on Genentech Inc.'s submission of two Biologics License Applications to the U.S. Food and Drug Administration (FDA) for Avastin for advance breast cancer therapy. It mentions that the drug met its primary endpoint of progression-free survival (PFS) in two separate studies. It...

The article reports that the Oncology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 5-4 that bevacizumab should not be approved for first-line treatment of metastatic breast cancer. The reason behind the decision was the presence of an increase in grade-three and...

The article presents an update on the action taken by the U.S. Food and Drug Administration (FDA), including the removal of the breast cancer indication for bevacizumab, the recommendation of the approval for the diet pill Contrave from Orexigen Therapeutics, and the approval of denosumab for...

The article explores the issues surrounding the use of Genetech's bevacizumab for the treatment of breast cancer. The U.S. Food and Drug Administration (FDA) has revoked the approval of the drug due to the lack of evidence of improved survival despite studies which have shown improvement in...

The author comments on the need for the U.S. Food and Drug Administration (FDA) to follow the recommendation of its advisory panels concerning the use of the drug Avastin from Genentech for the treatment of metastatic breast cancer. The article mentions that if the agency ignores the advice of...

The article focuses on the commercial setback encountered by Avastin bevacizumab from Genetech due to a negative vote over its use in metastatic breast cancer made by a U.S. Food and Drug Administration (FDA) advisory committee in July 2010. Avastin is known as the first drug capable of blocking...